Related Experiment Videos
Atrial natriuretic peptide in heart failure
R R Brandt1, R S Wright, M M Redfield
1Department of Internal Medicine, Mayo Clinic, Rochester, Minnesota 55905.
Journal of the American College of Cardiology
|October 1, 1993
Summary
Atrial natriuretic peptide (ANP) increases in heart failure, acting as a diagnostic marker. However, the kidneys become unresponsive to ANP, contributing to sodium retention and disease progression.
Area of Science:
- Cardiology
- Endocrinology
- Nephrology
Background:
- Atrial natriuretic peptide (ANP) is a cardiac hormone regulating sodium balance and inhibiting the renin-angiotensin-aldosterone system.
- Congestive heart failure (CHF) involves sodium retention due to increased cardiac load and neurohumoral activation.
- Circulating ANP levels significantly rise in CHF, reflecting increased synthesis and release.
Purpose of the Study:
- To explore the role of ANP in early heart failure.
- To investigate the mechanisms behind renal hyporesponsiveness to ANP in CHF.
- To discuss therapeutic strategies targeting ANP action.
Main Methods:
- Review of existing literature on ANP in heart failure.
- Analysis of ANP's diagnostic and prognostic significance.
- Examination of factors contributing to renal ANP resistance.
Main Results:
- Elevated ANP levels serve as a key diagnostic and prognostic marker in CHF.
- In early CHF, ANP may help maintain a compensated state in asymptomatic left ventricular dysfunction.
- Despite high circulating ANP, kidneys in CHF exhibit hyporesponsiveness, retaining sodium.
Conclusions:
- The attenuated renal response to ANP in CHF is multifactorial, involving renal hypoperfusion and activation of counter-regulatory systems.
- Potentiating ANP's biologic actions presents a therapeutic avenue to delay CHF progression.
- Understanding ANP resistance is crucial for developing effective CHF treatments.